Inventors:
Andrei P. Guzaev - Escondido CA, US
Matthew H. Adams - Zimmerman MN, US
Pei Ge - Cambridge MA, US
Muthiah Manoharan - Cambridge MA, US
Douglas Ulen Gwost - Shoreview MN, US
Gregory Robert Stewart - Plymouth MN, US
David Kent Stiles - Maple Grove MN, US
Brian Dale Nelson - Brichwood MN, US
William Frederick Kaemmerer - Edina MN, US
Don Marshall Gash - Lancaster KY, US
Assignee:
Alnylam Pharmaceuticals, Inc. - Cambridge MA
Medtronic, Inc. - Minneapolis MN
International Classification:
A61M 5/168, A61K 49/00, A61M 5/142, A61K 31/7088
US Classification:
6048911, 514 44 A, 424 91, 604151, 604503
Abstract:
This invention provides treatment compositions as well as systems and methods of determining and administering an effective amount of treatment for a neurological disorder. The treatment composition can contain a labeled interfering RNA (iRNA) agent capable of decreasing expression of a target RNA associated with the neurological disorder. The methods of the invention include determining an effective amount of a therapeutic composition by introducing a solution containing a tracer into the brain of a mammal. The tracing solution is monitored until a target volume of distribution at steady state distribution is substantially achieved, and the rate of delivery of the therapeutic composition is determined. The therapeutic composition can then be administered at the rate determined by use of the tracing solution.